Abstract: Methods to formulate treatments for individual cancer patients by assessing genomic and/or phenotypic differences between cancer and normal tissues and integrating the results to identify dysfunctional pathways are described.

Abstract: Apparatus for dissipating a fragrance or malodor eliminator utilizes an infused disc which a user can place in either a rotating or a fixed position. The two states will dissipate a scent/malodor-eliminator at different rates. The disc is mounted on a shaft that secures the disc in an air stream. The shaft defines several positions at which the disc can be placed, as well as structures to retain the disc at a selected location along the shaft. The shaft is part of a support which includes a mechanism for securing the apparatus within the air stream. Air flow causes the disc to rotate and dissipate at one rate or to pass through a stationary disc at a second, lower rate, as a function of the position of the disc on the shaft. A method of imparting a scent or malodor eliminator to air is also disclosed.

Abstract: Apparatus for dissipating a fragrance or malodor eliminator utilizes an infused disc which a user can place in either a rotating or a fixed position. The two states will dissipate a scent/malodor-eliminator at different rates. The disc is mounted on a shaft that secures the disc in an air stream. The shaft defines several positions at which the disc can be placed, as well as structures to retain the disc at a selected location along the shaft. The shaft is part of a support which includes a mechanism for securing the apparatus within the air stream. Air flow causes the disc to rotate and dissipate at one rate or to pass through a stationary disc at a second, lower rate, as a function of the position of the disc on the shaft. A method of imparting a scent or malodor eliminator to air is also disclosed.

Abstract: Methods to treat cancer patients, especially melanoma patients, who have BRAF mutations and have become resistant to BRAF mutant kinase inhibitors employ inhibitors of multiple receptor tyrosine kinases. In addition, methods are described for identifying pharmaceutical compositions and drugs that will be successful in treating these patients.

Abstract: Methods to treat cancer patients, especially melanoma patients, who have BRAF mutations and have become resistant to BRAF mutant kinase inhibitors employ inhibitors of multiple receptor tyrosine kinases. In addition, methods are described for identifying pharmaceutical compositions and drugs that will be successful in treating these patients.

Abstract: Methods to formulate treatments for individual cancer patients by assessing genomic and/or phenotypic differences between cancer and normal tissues and integrating the results to identify dysfunctional pathways are described.

Abstract: A method for treating an inflammatory disease of the digestive tract, for example inflammatory bowel disease, in a subject comprises administering to the subject a therapeutically effective amount of a compound selected from the group consisting of (S,S)-2-[1-carboxy-2-[3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl]-ethylamino]-4-methylpentanoic acid, pharmaceutically acceptable salts thereof and prodrugs thereof.